Abstracts - faqs.org

Abstracts

Retail industry

Search abstracts:
Abstracts » Retail industry

US: POTATO EXTRACT HELPS PREVENT DISEASES

Article Abstract:

Scientists from Miami University have revealed that an extract from the potato could help to prevent diseases. A compound in the potato called polyphenol oxidase (PPO) is said to inhibit bacterial adhesion, and is therefore said to prevent the attachment of E.coli to cells and also prevents the bug that caused tooth decay from clinging to teeth. Micro-organisms are said to secure themselves to target tissue to cause disease. By preventing the bacteria from attaching to tissue disease could be prevented. The discovery is expected to have a significant impact on the growing problem of drug-resistant bugs.

Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 2000
United States, Miami University (Ohio)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


UK: CRITICISM CUTS VALUATION OF OXFORD GLYCO

Article Abstract:

A broker's continued criticism of Oxford Glycosciences has wiped almost GB[pound] 100mn from the genomics company's valuation, after his letter was published in The Lancet. The letter, written by Dr P Mistry, questions the feasibility of Oxford's treatment for Gaucher's disease. As a result, shares in Oxford Glycoscience plummeted 11% to 17.35, cutting its valuation by GB[pound] 90mn to GB[pound] 702mn.

Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 2000
Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Financial analysis, Economic aspects, Finance, Oxford GlycoSciences PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Happy return to a biotech future?

Article Abstract:

Managing risk is the most significant challenge for pharmaceutical and biotechnology companies, according to Dr Andrew Millar, who revealed problems with drugs trials at British Biotech. He recognizes that companies with only one product are under very strong pressure to keep going, but feels that these companies must also take care to avoid becoming blind to potential problems. He still believes that there is hope for the drugs that British Biotech was developing.

Author: Arthur, Charles
Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 1999
Product development, Interview, British Biotech PLC, Millar, Andrew

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Biotechnology industry, Pharmaceutical industry, Biotechnology industries, Drugs, Biochemistry, United Kingdom
Similar abstracts:
  • Abstracts: UK: BRITISH FIRM SUES Y2K CONSULTANTS. Welcome to Silicon Beach. IT sets out its own market stall
  • Abstracts: UK: BRANSON NOT TO ACQUIRE EAST COAST RAIL. Double boost for Channel Tunnel. UK: PRISM RAIL TAKEOVER TALKS END
  • Abstracts: UK: SUCCESS OF INTERACTIVE TELEVISION SERVICE. And the beat goes on ... and on. UK: MORE TIME SPENT WATCHING TV
  • Abstracts: UK: BOO.COM RETURNS AS A RETAIL E-PORTAL. UK: REVIVAL FOR BOO.COM. UK: BOO.COM REVEALS JOB CUTS
  • Abstracts: Safe as houses (or flats or maisonettes). Watch this place: Wimbledon. UK: DECLINE IN LONDON HOUSE PRICES?
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.